Type 2 alveolar epithelial cell-derived circulating extracellular vesicle-encapsulated surfactant protein C as a mediator of cardiac inflammation in COVID-19.
Inflamm Res
; 71(9): 1003-1009, 2022 Sep.
Article
in English
| MEDLINE | ID: covidwho-1966115
ABSTRACT
Among the countless endeavours made at elucidating the pathogenesis of COVID-19, those aimed at the histopathological alterations of type 2 alveolar epithelial cells (AT2) are of outstanding relevance to the field of lung physiology, as they are the building blocks of the pulmonary alveoli. A merit of high regenerative and proliferative capacity, exocytotic activity resulting in the release of extracellular vesicles (EVs) is particularly high in AT2 cells, especially in those infected with SARS-CoV-2. These AT2 cell-derived EVs, containing the genetic material of the virus, might enter the bloodstream and make their way into the cardiovascular system, where they may infect cardiomyocytes and bring about a series of events leading to heart failure. As surfactant protein C, a marker of AT2 cell activity and a constituent of the lung surfactant complex, occurs abundantly inside the AT2-derived EVs released during the inflammatory stage of COVID-19, it could potentially be used as a biomarker for predicting impending heart failure in those patients with a history of cardiovascular disease.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Extracellular Vesicles
/
COVID-19
/
Heart Failure
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Inflamm Res
Journal subject:
Allergy and Immunology
/
Pathology
Year:
2022
Document Type:
Article
Affiliation country:
S00011-022-01612-z
Similar
MEDLINE
...
LILACS
LIS